#side-effects

9 articles tagged #side-effects.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4 #503a 1 #503b 2 #FDA 1 #alternatives 1 #ban 1 #before-and-after 1 #beginners 2 #brand-name 3 #bridge-program 1 #cagrilintide 1 #cagrisema 1 #comparison 2 #compounded 8 #compounded-semaglutide 1 #compounded-tirzepatide 1 #compounding-ban 1 #copay 1 #cost 13 #coupon 1 #coverage 1 #diabetes 1 #diet 1 #dosage 1 #eli-lilly 3 #enforcement 1 #enrollment 1 #fact-check 1 #fda 3 #fda-approval 1 #flat-rate 1 #foundayo 7 #framework 1 #glp-1-patches 1 #glucose-monitors 1 #guide 1 #hhs 1 #hims 1 #how-to-get 1 #injectable 7 #injection 1 #insulin-resistance 1 #insurance 11 #ivy-rx 1 #ivyrx 1 #legality 1 #liraglutide 1 #medicaid 1 #medicare 5 #mounjaro 6 #news 2 #novo-nordisk 2 #oral-glp1 6 #oral-semaglutide 1 #orforglipron 4 #ozempic 7 #pcos 1 #pill 1 #pipeline 1 #policy 1 #prior-authorization 2 #regulation 2 #results 1 #rfk 1 #ro 1 #safety 3 #savings-card 1 #schedule 1 #semaglutide 19 #shortage 1 #side-effects 9 #supplements 1 #surmount 2 #surmount-5 1 #telehealth-enforcement 1 #telehealth-review 1 #timeline 1 #tirzepatide 18 #type-2-diabetes 1 #warning-letters 1 #wegovy 16 #wegovy-hd 1 #wegovy-pill 3 #weight-loss 26 #without-insurance 1 #zepbound 17

Editorial still-life illustrating a comparison of Wegovy and Zepbound for weight loss

Analysis ComparisonsJune 17, 2026• 14 min read

Wegovy vs Zepbound (June 2026): SURMOUNT-5 Head-to-Head, Wegovy HD, & Cost Comparison

Updated June 2026: SURMOUNT-5 head-to-head trial (NEJM): Zepbound 20.2% vs Wegovy 13.7% weight loss at 72 weeks. Wegovy HD (7.2mg, FDA-approved March 2026) closes the gap at 20.7%. Wegovy self-pay: $349/mo (NovoCare). Zepbound self-pay: $299-$449/mo (LillyDirect). Both $25/mo with commercial insurance + savings card.

Editorial still-life illustrating retatrutide, a Phase 3 triple-agonist weight loss drug

Analysis News & PipelineJune 10, 2026• 11 min read

Retatrutide TRIUMPH-1 Results (May 2026): 30.3% Weight Loss, Phase 3 Primary Trial

Updated June 10, 2026 (ADA 2026 full dataset): Retatrutide Phase 3 program complete. Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. Comorbidities (ADA June 2026): TRIUMPH-4 knee OA, WOMAC pain score −4.0 points (≈75% reduction) vs −2.1 placebo; 14.1% pain-free on 9mg vs 4.2% placebo. TRIUMPH-1 OSA secondary: 60.6% AHI reduction (58.6 → ~23 events/hr). NDA expected Q4 2026.

Editorial lifestyle photograph illustrating a guide to Foundayo orforglipron oral GLP-1

Guide GuidesApril 29, 2026• 14 min read

Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions, take any time.

Editorial lifestyle still-life accompanying a guide to Zepbound side effects and management

Guide Side Effects & SafetyApril 20, 2026• 10 min read

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13%, Full Guide with SURMOUNT Trial Data

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

Editorial lifestyle photograph illustrating a beginner guide to GLP-1 weight loss medications

Guide GuidesApril 13, 2026• 12 min read

GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Editorial photograph illustrating what to expect during the first month on a GLP-1 medication

Guide GuidesApril 11, 2026• 8 min read

First Month on GLP-1 (2026): 2-5 lbs Lost Week 1-4, Nausea Peaks Week 4, Week-by-Week

Verified April 2026: GLP-1 patients lose 2-5 pounds in their first month. Appetite suppression starts week 1-2. Nausea peaks at week 4 dose escalation. 98.1% of GI side effects are mild-to-moderate per STEP-1 and SURMOUNT-1 trials. Complete week-by-week timeline with dosing schedule.

Editorial lifestyle photograph illustrating foods to avoid while taking GLP-1 medications

Guide Side Effects & SafetyApril 11, 2026• 10 min read

Foods to Avoid on GLP-1 (2026): 7 Worst Offenders + What to Eat Instead

Verified April 2026: The 7 worst foods on Ozempic, Wegovy, Zepbound, fried food, sugary drinks, red meat portions, raw cruciferous veg, carbonated beverages, alcohol, high-fiber bars. GLP-1s slow gastric emptying 25-40%, triggering nausea in 44% of patients. Full list with alternatives.

Editorial still-life illustrating a guide to GLP-1 side effects and management

Guide Side Effects & SafetyApril 11, 2026• 12 min read

GLP-1 Side Effects (2026): Nausea 44%, Diarrhea 30%, Vomiting 24%, Complete Management Guide

Verified April 2026: 44% of Wegovy patients report nausea, 30% diarrhea, 24% vomiting in STEP-1 trial. Only 7% discontinued for side effects. Tirzepatide (Zepbound) is more tolerable: 24-33% nausea, 7-13% vomiting per SURMOUNT-1. Full management guide with red flags.

Editorial still-life illustrating the FDA approval of Foundayo orforglipron oral GLP-1

News News & PipelineApril 2, 2026• 10 min read

Foundayo (Orforglipron) FDA Approved: The First GLP-1 Weight Loss Pill You Can Take Anytime

The FDA just approved Eli Lilly's Foundayo (orforglipron), the only GLP-1 weight loss pill with no food, water, or timing restrictions. Here's what it costs, how it works, and how it compares to Wegovy and Zepbound.